Suk Hwang Park

Title: Innovations of Suk Hwang Park in Bacteriophage Research

Introduction

Suk Hwang Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of bacteriophage research, holding a total of 3 patents. His work focuses on developing innovative methods to combat bacterial infections using naturally occurring bacteriophages.

Latest Patents

Among his latest patents is the bacteriophage Bor-BRP-1, which is a Podoviridae bacteriophage isolated from nature. This bacteriophage has the ability to specifically kill bacteria and is represented by a genome with the accession number KCTC 12705BP. The invention includes a method for preventing and treating bacterial infections using a composition that comprises this bacteriophage as an active ingredient. Another significant patent is the Myoviridae bacteriophage Esc-COP-1, which can specifically target Shigatoxin-producing type F18 strains. This bacteriophage is also isolated from nature and has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1, with the accession number KCTC 12662BP. The invention outlines a method for preventing and treating infections caused by Shigatoxin-producing type F18 using a composition that includes this bacteriophage.

Career Highlights

Suk Hwang Park is currently associated with Intron Biotechnology, Inc., where he continues to advance his research in bacteriophage technology. His work has the potential to revolutionize the way bacterial infections are treated, providing new avenues for therapeutic interventions.

Collaborations

He collaborates with talented coworkers, including Seong Jun Yoon and Sang Hyeon Kang, who contribute to the innovative research environment at Intron Biotechnology, Inc.

Conclusion

Suk Hwang Park's contributions to bacteriophage research exemplify the importance of innovation in combating bacterial infections. His patents reflect a commitment to advancing medical science and improving public health.